Navigation

Skiplink Navigation

Main Features

Baxter investment triples the company workforce in Neuchâtel

The United States pharmaceutical group, Baxter, is to create 300 more jobs at its plant in Neuchâtel over the next three years, investing a total of SFr210 million Swiss francs.

The United States pharmaceutical group, Baxter, is to create 300 more jobs at its plant in Neuchâtel over the next three years, investing a total of SFr210 million Swiss francs.

The group announced in Brussels on Wednesday that it was making total investments of SFr660 million in its Hyland Immuno division at production sites in Switzerland, Austria and California.

The Swiss site, which opened in 1995, is to manufacture a product used in the treatment of haemophilia. The plant currently has 120 employees.

Hyland Immuno produces vaccines, preparations from plasma and various drugs used in the treatment of

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

×